Treats infantile spasms. Sold as Acthar, Acth, Acthar Gel, Purified Cortrophin Gel, Corticotropin. Every FDA application for this active ingredient: 5 branded and 1 generic.
As of Nov 14, 2026, FDA lists 6 applications for Corticotropin (sold as Acthar, Acth, Acthar Gel and others), first approved Jul 3, 1950, with 2 new uses approved and 0 published complete response letters.
| Acthar Selfject | Part D | $338M | +941% | 1,052 |
| Acthar | Part D | $286M | -21% | 604 |
| Cortrophin | Part D | $264M | +103% | 1,136 |
| Cortrophin | Part B | $4.3M | +790% | 114 |
| Corticotropin for Behçet's Disease: A Multicenter Randomized Controlled TrialAcronym.Behçet's Syndrome, Behçet's Syndrome (BS) · Peking University People's Hospital | Phase 2 | Not yet recruiting | Sep 22, 2026 |
| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of OMS1620Congenital Adrenal Hyperplasia (CAH) · OMass Therapeutics Australia Proprietary Ltd | Phase 1 | Not yet recruiting | Sep 9, 2026 |
| Combination Osilodrostat and Cabergoline in Cushing's DiseaseCushing Disease Due to Increased ACTH Secretion · University of Basrah | Phase 4 | Enrolling by invitation | May 22, 2026 |
| FET PET/CT Imaging To Localize Pituitary Adenomas In Cushing DiseaseCushing Disease, Pituitary Adenoma · Mayo Clinic | Early phase 1 | Recruiting | Mar 10, 2026 |
| A Phase 2 Study to Evaluate the Effects of ASP5541 in Participants With Prostate CancerProstate Cancer, Metastatic Castration-Resistant Prostate Cancer · Astellas Pharma Global Development, Inc. | Phase 2 | Recruiting | Jun 5, 2025 |
| Correlation of Psychological Distress and Immune Checkpoint Inhibitors in Gastric CancerGastric Cancers · Nanfang Hospital, Southern Medical University | — | Recruiting | Jun 4, 2025 |
| Use of Acthar Gel Single-Dose Pre-Filled SelfJectTM Injector in Patients With Moderate-Severe Keratitis and Autoimmune DiseaseAutoimmune Diseases, Dry Eye · Toyos Clinic | Phase 4 | Recruiting | May 9, 2025 |
| Modified Desmopressin (mDesmo) Using Cold-Kit for PET/CTCushing Syndrome · Post Graduate Institute of Medical Education and Research, Chandigarh | — | Recruiting | May 8, 2025 |
| Jul 3, 1950 | ActharNDA 7504 · New molecular entity | Sanofi Aventis US | 9 | Discontinued |
| Mar 14, 1952 | ActhNDA 8317 · New formulation or manufacturer | Parkedale | 8 | Discontinued |
| Apr 29, 1952 | Acthar GelNDA 8372 · New formulation or manufacturer | Mallinckrodt Ireland | 32 | Marketed |
| Jun 16, 1954 | Purified Cortrophin GelNDA 8975 · New formulation or manufacturer | Ani Pharms | 7 | Marketed |
| Sep 12, 1957 | CorticotropinNDA 10831 · New dosage form | Organics Lagrange | 16 | Discontinued |
| — | CorticotropinANDA 88772 | Watson Labs | 0 | Discontinued |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
Sanofi Aventis US